Platelet-biomimetic nanoparticles for in vivo targeted photodynamic therapy of breast cancer
Source abstract
Abstract
Nanocarrier-based photodynamic therapy (PDT) has emerged as a promising treatment in cancer therapy. However, the PDT therapeutic efficacy is limited by the lack of specificity, limited intracellular cytotoxic reactive oxygen species (ROS) generation, and the immunosuppressive tumor microenvironment. Herein, a platelet membrane (Pm) decorated and chlorin e6 loaded liposome (Pm/Lps/Ce6) is developed to improve specific tumor-targeting capability and antitumor responses. Pm/Lps/Ce6 could efficiently improve the cellular internalization of Ce6. Under 660-nm laser irradiation, enough ROS was produced to suppress the growth of tumor cells in vitro. In vivo, the Pm decoration increased cellular uptake of the Ce6 loaded liposome in cancer cells by the tumor-targeting and immune escape capacity and produced a satisfactory inhibitory effect on breast cancer. Our study provides a biomimetic strategy via the biological properties of Pm to improve the antitumor performance of photodynamic therapy for treating breast cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Nursing Platform for Breast Surgery, The First Hospital of Jilin University, Changchun, China
Department of Operation Room, The First Hospital of Jilin University, Changchun, China
Funding
Scientific Development Program of Jilin Province
References (28)
Show source-provided references
1. 10.1016/j.biomaterials.2011.07.02310.1016/j.biomaterials.2011.07.023 ↗
2. 10.1002/ange.20151134510.1002/ange.201511345 ↗
3. 10.1021/acsami.1c0681810.1021/acsami.1c06818 ↗
4. 10.1021/acsami.0c1404610.1021/acsami.0c14046 ↗
5. 10.1016/j.biopha.2020.11044310.1016/j.biopha.2020.110443 ↗
6. 10.2147/IJN.S28944310.2147/IJN.S289443 ↗
7. 10.1016/j.xphs.2020.12.03410.1016/j.xphs.2020.12.034 ↗
8. 10.1002/ange.20110476510.1002/ange.201104765 ↗
9. 10.1021/acsami.7b1645510.1021/acsami.7b16455 ↗
10. 10.1039/C5NR07785K10.1039/C5NR07785K ↗
11. 10.1021/ja038690510.1021/ja0386905 ↗
12. 10.1002/anie.20151074810.1002/anie.201510748 ↗
13. 10.1021/ja505212y10.1021/ja505212y ↗
14. 10.3390/pharmaceutics1203024710.3390/pharmaceutics12030247 ↗
15. 10.1038/nnano.2006.17010.1038/nnano.2006.170 ↗
16. 10.1210/en.2009-108210.1210/en.2009-1082 ↗
17. 10.1016/j.jconrel.2018.09.03010.1016/j.jconrel.2018.09.030 ↗
18. 10.1021/acsami.9b1122310.1021/acsami.9b11223 ↗
19. 10.2174/156802662066620092211305410.2174/1568026620666200922113054 ↗
20. 10.2217/nnm-2019-038810.2217/nnm-2019-0388 ↗
21. 10.1002/advs.20190060510.1002/advs.201900605 ↗
22. 10.1038/nmat464410.1038/nmat4644 ↗
23. 10.1016/j.jconrel.2018.12.01910.1016/j.jconrel.2018.12.019 ↗
24. 10.1002/adma.20170675910.1002/adma.201706759 ↗
25. 10.1021/acsnano.6b0314810.1021/acsnano.6b03148 ↗
26. 10.1002/adfm.20160477410.1002/adfm.201604774 ↗
27. 10.7150/thno.1855710.7150/thno.18557 ↗
28. 10.2217/nnm.12.15310.2217/nnm.12.153 ↗